Literature DB >> 22205193

Uncoupling the dopamine D1-D2 receptor complex: a novel target for antidepressant treatment.

A H C Wong1, F Liu.   

Abstract

Depression, or major depressive disorder (MDD), is a serious mental illness that causes substantial worldwide disability. Current antidepressant medications mostly target the serotonin and norepinephrine neurotransmitter systems. These drugs are ineffective in many patients, and there are limited options for treatment-resistant depression. The dopamine neurotransmitter system has recently been identified as another modulator of mood and depressive symptoms, and a recently discovered interaction between the dopamine D1 and D2 receptor may be a novel antidepressant target.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22205193     DOI: 10.1038/clpt.2011.311

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  5 in total

1.  Intranasal delivery of a peptide with antidepressant-like effect.

Authors:  Virginia Brown; Fang Liu
Journal:  Neuropsychopharmacology       Date:  2014-03-17       Impact factor: 7.853

2.  Dysregulation of Striatal Dopamine Receptor Binding in Suicide.

Authors:  Megan L Fitzgerald; Suham A Kassir; Mark D Underwood; Mihran J Bakalian; J John Mann; Victoria Arango
Journal:  Neuropsychopharmacology       Date:  2016-07-12       Impact factor: 7.853

3.  Heterodimerization with the prostacyclin receptor triggers thromboxane receptor relocation to lipid rafts.

Authors:  Salam Ibrahim; Ann McCartney; Nune Markosyan; Emer M Smyth
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-11-15       Impact factor: 8.311

4.  Antidepressant-like effects of lycii radicis cortex and betaine in the forced swimming test in rats.

Authors:  Soo Jeong Kim; Lee Lee; Ji Hyun Kim; Tae Hee Lee; Insop Shim
Journal:  Biomol Ther (Seoul)       Date:  2013-01       Impact factor: 4.634

5.  Understanding resilience.

Authors:  Gang Wu; Adriana Feder; Hagit Cohen; Joanna J Kim; Solara Calderon; Dennis S Charney; Aleksander A Mathé
Journal:  Front Behav Neurosci       Date:  2013-02-15       Impact factor: 3.558

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.